CN109288796A - Composite sulfamonomethoxine soluble powder of sodium - Google Patents
Composite sulfamonomethoxine soluble powder of sodium Download PDFInfo
- Publication number
- CN109288796A CN109288796A CN201811351675.5A CN201811351675A CN109288796A CN 109288796 A CN109288796 A CN 109288796A CN 201811351675 A CN201811351675 A CN 201811351675A CN 109288796 A CN109288796 A CN 109288796A
- Authority
- CN
- China
- Prior art keywords
- sodium
- powder
- soluble powder
- composite sulfamonomethoxine
- sulfamonomethoxine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of composite sulfamonomethoxine soluble powder of sodium, the raw material including following quality: 9.0~10.5kg of Sulfamonomethoxime Sodium, 2~3kg of TMP, 8.0~12.0kg of 51.0~53.0kg of glucose, 4.0~6.0kg of sodium bicarbonate plus beneficial powder, 18.0~25.0kg of anhydrous sodium sulphate, 0.1~1.0kg of resistive connection powder.Of the invention novel in design, formula rationally, and can reach effective antibacterial and bactericidal effect, so that infection caused by sensitive bacteria, if respiratory tract, alimentary canal infection and chicken coccidiasis, Chicken Leucocyte Pest are significantly treated, effect is obvious.
Description
Technical field
The present invention relates to disulfonamide technical field more particularly to a kind of composite sulfamonomethoxine sodium are soluble
Powder.
Background technique
In existing aquaculture, chicken is generally adopted captive breeding method, and is raised for big quantity, since quantity is multi-environment small,
So that chicken is easy to generate disease, and disease is easy to propagate, for example existing chicken can be because infection caused by sensitive bacteria, be such as exhaled
Inhale road, alimentary canal infection and chicken coccidiasis, Chicken Leucocyte Pest.
But not there is significant therapeutic effect to above-mentioned disease in existing drug, so that being born for raising family
Great disease risks.
Summary of the invention
The purpose of the present invention is to solve existing drugs cannot treat infection caused by sensitive bacteria well, such as breathes
The shortcomings that road, alimentary canal infection and chicken coccidiasis, Chicken Leucocyte Pest, and a kind of composite sulfamonomethoxine sodium proposed
Soluble powder.
To achieve the goals above, present invention employs following technical solutions:
Composite sulfamonomethoxine soluble powder of sodium, the raw material including following quality: Sulfamonomethoxime Sodium 9.0~
2~3kg of 10.5kg, TMP, 8.0~12.0kg of 51.0~53.0kg of glucose, 4.0~6.0kg of sodium bicarbonate plus beneficial powder, member are bright
18.0~25.0kg of powder, 0.1~1.0kg of resistive connection powder.
Preferably, the raw material including following quality: Sulfamonomethoxime Sodium 9.7kg, TMP 2.4kg, glucose
52.4kg, sodium bicarbonate 5.0kg plus beneficial powder 10.0kg, anhydrous sodium sulphate 20.0kg, resistive connection powder 0.5kg.
Preferably, described plus beneficial powder is using white type.
The application method of composite sulfamonomethoxine soluble powder of sodium, including step used below:
S1: cold boiled water water 1L is taken, 1~2g of soluble powder is added to stir and evenly mix；
S2: mixed liquid medicine being poured into clean water fountain, drunk to chicken, is used in conjunction 3~5.
Preferably, the composite sulfamonomethoxine soluble powder of sodium is disabled in laying cycle of laying hens.
Preferably, the composite sulfamonomethoxine soluble powder of sodium continuous use was no more than one week.
The beneficial effects of the present invention are: daimeton inhibits dihydrofoilic acid by competition dihydrofolate synthetase
Synthesis, finally makes nucleic acid biosynthesis block, and bacterial growth breeding is caused to be prevented from；Trimethoprim is by inhibiting dihydrofolate reduction
Enzyme prevents dihydrofoilic acid from being reduced into tetrahydrofolic acid, so that thallus nucleic acid be interfered to synthesize.Daimeton and trimethoprim
It shares, synergetic antibacterial effect can be generated with the metabolism of double blocking folic acid；
Of the invention novel in design, formula rationally, and can reach effective antibacterial and bactericidal effect, so that caused by sensitive bacteria
Infection, if respiratory tract, alimentary canal infection and chicken coccidiasis, Chicken Leucocyte Pest are significantly treated, effect is obvious.
Specific embodiment
The following is a clear and complete description of the technical scheme in the embodiments of the invention, it is clear that described embodiment
Only a part of the embodiment of the present invention, instead of all the embodiments.
Embodiment one
Composite sulfamonomethoxine soluble powder of sodium proposed by the present invention, the raw material including following quality: methoxy is phonetic between sulfanilamide (SN)
Pyridine sodium 9.5kg, TMP 2.3kg, glucose 52.8kg, sodium bicarbonate 4.5kg plus beneficial powder 11.0kg, anhydrous sodium sulphate 19.0kg, resistive connection powder
0.75kg。
Embodiment two
Composite sulfamonomethoxine soluble powder of sodium proposed by the present invention, the raw material including following quality: methoxy is phonetic between sulfanilamide (SN)
Pyridine sodium 10.1kg, TMP 2.8kg, glucose 52.9kg, sodium bicarbonate 5.5kg plus beneficial powder 11.5kg, anhydrous sodium sulphate 24.0kg, resistive connection
Powder 0.9kg.
Embodiment three
Composite sulfamonomethoxine soluble powder of sodium proposed by the present invention, the raw material including following quality: methoxy is phonetic between sulfanilamide (SN)
Pyridine sodium 9.7kg, TMP 2.4kg, glucose 52.4kg, sodium bicarbonate 5.0kg plus beneficial powder 10.0kg, anhydrous sodium sulphate 20.0kg, resistive connection powder
0.5kg。
Example IV
Composite sulfamonomethoxine soluble powder of sodium proposed by the present invention, the raw material including following quality: methoxy is phonetic between sulfanilamide (SN)
Pyridine sodium 10.4kg, TMP 2.7kg, glucose 51.8kg, sodium bicarbonate 4.8kg plus beneficial powder 9.5kg, anhydrous sodium sulphate 19.5kg, resistive connection powder
0.8kg。
The drug for taking market for treating three kinds of drug of the generic disease of chicken, and taking aforementioned four embodiment worth,
And drug equivalent in seven cultivates sensitive bacteria under equal conditions in 21 culture dishes, obtains germ and tests object, and by 21 cultures
Ware is divided into seven groups, a kind of every group of drug of correspondence, and under equal conditions every group of culture dish instills equivalent liquid medicine, after one day, two
Change after it and by the germ quantity in micro- sem observation culture dish after three days, obtain following data:
By above-mentioned data it is found that pharmaceutical formulation proposed by the present invention, is substantially better than existing in the effect for inhibiting and killing germ
Commercioganic drug, and the comparison in embodiment one to four, it is known that embodiment three matches specific mass effect achieved most
Obviously, so as to obtain embodiment three be optimal proportion.
The composite sulfamonomethoxine soluble powder of sodium of preparation, to the application method of chicken, comprising the following steps:
S1: cold boiled water water 1L is taken, 1~2g of soluble powder is added to stir and evenly mix；
S2: mixed liquid medicine being poured into clean water fountain, drunk to chicken, is used in conjunction 3~5.
And daimeton inhibits the synthesis of dihydrofoilic acid by competition dihydrofolate synthetase, finally makes nucleic acid
Biosynthesis block causes bacterial growth breeding to be prevented from；Trimethoprim by inhibit dihyrofolate reductase, prevent dihydrofoilic acid from
It is reduced into tetrahydrofolic acid, so that thallus nucleic acid be interfered to synthesize.Daimeton is shared with trimethoprim, can be with double blocking
The metabolism of folic acid generates synergetic antibacterial effect.
Also, for continuous use no more than one week, long-time service can damage kidney and nervous system, influence to increase weight, and can
Sulfa drug poisoning can occur.
The drug of preparation is in shading, closed, the preservation at shady and cool drying, laying cycle of laying hens disabling.
The foregoing is only a preferred embodiment of the present invention, but scope of protection of the present invention is not limited thereto,
Anyone skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Inventive concept is subject to equivalent substitution or change, should be covered by the protection scope of the present invention.
Claims (6)
1. composite sulfamonomethoxine soluble powder of sodium, which is characterized in that the raw material including following quality: methoxy is phonetic between sulfanilamide (SN)
9.0~10.5kg of pyridine sodium, 2~3kg of TMP, 51.0~53.0kg of glucose, 4.0~6.0kg of sodium bicarbonate plus beneficial powder 8.0~
12.0kg, 18.0~25.0kg of anhydrous sodium sulphate, 0.1~1.0kg of resistive connection powder.
2. composite sulfamonomethoxine soluble powder of sodium according to claim 1, which is characterized in that including following quality
Raw material: Sulfamonomethoxime Sodium 9.7kg, TMP 2.4kg, glucose 52.4kg, sodium bicarbonate 5.0kg plus beneficial powder 10.0kg,
Anhydrous sodium sulphate 20.0kg, resistive connection powder 0.5kg.
3. composite sulfamonomethoxine soluble powder of sodium according to claim 1, which is characterized in that described plus beneficial powder is adopted
With white type.
4. the application method of composite sulfamonomethoxine soluble powder of sodium, which comprises the following steps:
S1: cold boiled water water 1L is taken, 1~2g of soluble powder is added to stir and evenly mix；
S2: mixed liquid medicine being poured into clean water fountain, drunk to chicken, is used in conjunction 3~5.
5. the application method of composite sulfamonomethoxine soluble powder of sodium according to claim 4, which is characterized in that institute
Composite sulfamonomethoxine soluble powder of sodium is stated to disable in laying cycle of laying hens.
6. the application method of composite sulfamonomethoxine soluble powder of sodium according to claim 4, which is characterized in that institute
Composite sulfamonomethoxine soluble powder of sodium continuous use is stated no more than one week.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811351675.5A CN109288796A (en) | 2018-11-14 | 2018-11-14 | Composite sulfamonomethoxine soluble powder of sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811351675.5A CN109288796A (en) | 2018-11-14 | 2018-11-14 | Composite sulfamonomethoxine soluble powder of sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109288796A true CN109288796A (en) | 2019-02-01 |
Family
ID=65146712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811351675.5A Pending CN109288796A (en) | 2018-11-14 | 2018-11-14 | Composite sulfamonomethoxine soluble powder of sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109288796A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110484640A (en) * | 2019-08-15 | 2019-11-22 | 华中农业大学 | The ARMS-PCR primer and its molecular detecting method of sulfanilamide (SN) drug resistance Eimeria Tenella |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450055A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease |
| CN101468027A (en) * | 2007-12-26 | 2009-07-01 | 天津瑞普生物技术集团有限公司 | Soluble powder for preventing and treating coccidiosis of livestock and poultry |
| CN101836995A (en) * | 2010-04-29 | 2010-09-22 | 湖南农业大学 | Compound sulfamonomethoxine sodium multivesicular liposome and preparation method thereof |
| CN104623058A (en) * | 2015-01-15 | 2015-05-20 | 郑州都灵兽药科技有限公司 | Preparation method of micro-ecological traditional Chinese medicine effervescent granule |
-
2018
- 2018-11-14 CN CN201811351675.5A patent/CN109288796A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450055A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease |
| CN101468027A (en) * | 2007-12-26 | 2009-07-01 | 天津瑞普生物技术集团有限公司 | Soluble powder for preventing and treating coccidiosis of livestock and poultry |
| CN101836995A (en) * | 2010-04-29 | 2010-09-22 | 湖南农业大学 | Compound sulfamonomethoxine sodium multivesicular liposome and preparation method thereof |
| CN104623058A (en) * | 2015-01-15 | 2015-05-20 | 郑州都灵兽药科技有限公司 | Preparation method of micro-ecological traditional Chinese medicine effervescent granule |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110484640A (en) * | 2019-08-15 | 2019-11-22 | 华中农业大学 | The ARMS-PCR primer and its molecular detecting method of sulfanilamide (SN) drug resistance Eimeria Tenella |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101657197B (en) | Antifungal is for the preparation of the purposes of the compositions for the treatment of fish mycoses | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN105124175A (en) | Organic breeding method for phasianus colchicus Linnaeus and bred phasianus colchicus Linnaeus | |
| CN105287790B (en) | A kind of fevervine extract and its application | |
| CN106822092B (en) | A kind of pharmaceutical composition inhibiting infected by Aeromonas hydrophila | |
| CN109288796A (en) | Composite sulfamonomethoxine soluble powder of sodium | |
| CN106577480A (en) | Breeding method for improving disease resistance of cattle | |
| WO2007117102A1 (en) | Complex antibiotic composition for bovine mastitis | |
| CN109996554A (en) | Novel antimicrobial and anti-cancer therapies | |
| CN101708187B (en) | Dry powder preparation for preventing and controlling saprolegniasis of aquatic animals and preparation method thereof | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN105998036B (en) | One boar fowl compound sulfonamide Nitazoxanide soluble powder | |
| CN101829129A (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN107348147A (en) | Fragrant duck feed addictive | |
| CN102920718B (en) | The application of phenylethanoid glycoside monomeric compound | |
| CN104739857A (en) | Pharmaceutical composition for treating dermatomycosis of young rabbits | |
| CN110368429A (en) | Prevent and treat the Chinese medicine composition and preparation method thereof that bacillary enterogastritis draws dysentery | |
| CN109331026A (en) | Tigecycline is preparing the application in anti-Huppert's disease drug | |
| CN108186617A (en) | The new application of geraniol and its derivative in MRSA infectious disease medicaments are prepared | |
| CN105456281B (en) | A kind of veterinary medical composition and its production and use | |
| CN114129635B (en) | Antibacterial composition containing capsicum extract and its application | |
| WO2024140295A1 (en) | Pharmaceutical combination for treating tumors and use thereof | |
| CN108992448B (en) | Salt-containing degerming tablet for aquarium fish and preparation method thereof | |
| CN105796693B (en) | A kind of pharmaceutical composition and its preparation method and application preventing and treating Diphterin type pox | |
| CN104784182B (en) | It is a kind of to treat composition of livestock and poultry diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190201 |
|
| RJ01 | Rejection of invention patent application after publication |